Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
53
AUTL Quote, Financials, Valuation and Earnings
Last price:
$1.65
Seasonality move
:
-17.34%
Day range:
$1.50 - $1.65
52-week range:
$1.11 - $2.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.52x
P/B ratio:
2.19x
Volume:
1.7M
Avg. volume:
1.8M
1-year change:
-18%
Market cap:
$436.5M
Revenue:
$10.1M
EPS (TTM):
-$0.84
Analysts' Opinion
-
Consensus RatingAutolus Therapeutics Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.99, Autolus Therapeutics Plc has an estimated upside of 448.17% from its current price of $1.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing -204.88% downside risk from its current price of $1.64.
Fair Value
-
According to the consensus of 10 analysts, Autolus Therapeutics Plc has 448.17% upside to fair value with a price target of $8.99 per share.
AUTL vs. S&P 500
-
Over the past 5 trading days, Autolus Therapeutics Plc has overperformed the S&P 500 by 14.26% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Autolus Therapeutics Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Autolus Therapeutics Plc revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Autolus Therapeutics Plc reported revenues of $21.1M.
Earnings Growth
-
Autolus Therapeutics Plc has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Autolus Therapeutics Plc reported earnings per share of -$0.30.
Enterprise value:
392.7M
EV / Invested capital:
--
Price / LTM sales:
8.52x
EV / EBIT:
--
EV / Revenue:
7.66x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$41.3M
Return On Assets:
-30.04%
Net Income Margin (TTM):
-438.34%
Return On Equity:
-59.51%
Return On Invested Capital:
-32.68%
Operating Margin:
-337.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $5.6M | $10.1M | $51.3M | -- | $21.1M | |
| Gross Profit | -$965.2K | $2.7M | -$41.3M | -$1.9M | -$10.8M | |
| Operating Income | -$152.8M | -$205.8M | -$273.5M | -$67.7M | -$71.2M | |
| EBITDA | -$146.3M | -$198.4M | -$263.4M | -$65.7M | -$67.8M | |
| Diluted EPS | -$0.91 | -$1.21 | -$0.84 | -$0.31 | -$0.30 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $236.4M | $212M | $306.5M | $715.9M | $511.2M | |
| Total Assets | $296.6M | $263.8M | $406.1M | $827.5M | $661.9M | |
| Current Liabilities | $34.6M | $38.8M | $37.5M | $52.5M | $83.1M | |
| Total Liabilities | $51.9M | $102.7M | $225.6M | $350.5M | $396.5M | |
| Total Equity | $244.7M | $161.2M | $180.5M | $477M | $265.5M | |
| Total Debt | $21.8M | $11.3M | $47M | $297.6M | $320.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$135.3M | -$193.2M | -$255M | -$76.7M | -$67.4M | |
| Cash From Investing | -$10.1M | -$12.4M | -$311.4M | -$9.6M | $35.5M | |
| Cash From Financing | $222.5M | $559.6M | $27.5M | $185K | -$1.8M | |
| Free Cash Flow | -$145.4M | -$205.6M | -$306.9M | -$86.3M | -$79.9M | |
AUTL
Sector
Market Cap
$436.5M
$25.2M
Price % of 52-Week High
60.74%
49.83%
Dividend Yield
0%
0%
Shareholder Yield
-1.68%
-1.77%
1-Year Price Total Return
-18%
-21.9%
Beta (5-Year)
1.979
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.48
200-day SMA
Sell
Level
$1.72
Bollinger Bands (100)
Buy
Level
1.36 - 1.7
Chaikin Money Flow
Sell
Level
-113.3M
20-day SMA
Buy
Level
$1.44
Relative Strength Index (RSI14)
Buy
Level
61.21
ADX Line
Buy
Level
16.71
Williams %R
Sell
Level
-2.9412
50-day SMA
Buy
Level
$1.56
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
60.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.9133)
Sell
CA Score
(Annual)
Level (-2.3406)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.2615)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Stock Forecast FAQ
In the current month, AUTL has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AUTL average analyst price target in the past 3 months is $8.99.
-
Where Will Autolus Therapeutics Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Autolus Therapeutics Plc share price will rise to $8.99 per share over the next 12 months.
-
What Do Analysts Say About Autolus Therapeutics Plc?
Analysts are divided on their view about Autolus Therapeutics Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Autolus Therapeutics Plc is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Autolus Therapeutics Plc's Price Target?
The price target for Autolus Therapeutics Plc over the next 1-year time period is forecast to be $8.99 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AUTL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Autolus Therapeutics Plc is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AUTL?
You can purchase shares of Autolus Therapeutics Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Autolus Therapeutics Plc shares.
-
What Is The Autolus Therapeutics Plc Share Price Today?
Autolus Therapeutics Plc was last trading at $1.65 per share. This represents the most recent stock quote for Autolus Therapeutics Plc. Yesterday, Autolus Therapeutics Plc closed at $1.64 per share.
-
How To Buy Autolus Therapeutics Plc Stock Online?
In order to purchase Autolus Therapeutics Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AUTL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AUTL
Sector
P/E ratio
--
23.30x
PEG ratio
--
-0.01x
P/B ratio
2.19x
1.78x
Price / LTM sales
8.52x
1.55x
Growth Metrics
AUTL
Sector
Revenue growth
-10.99%
3.69%
Earnings growth
4.21%
9.95%
Revenue (5-year growth)
--
6.38%
Earnings forecast
-$0.43
-$0.19
Profitability
AUTL
Sector
Profitability FY 2024
-$9M
$2.6M
Return on invested capital
-32.68%
-33.25%
Return on assets
-30.04%
-29.67%
Return on equity
-59.51%
-38.66%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
11
Balance Sheet
AUTL
Sector
Total cash
$368.9M
$25.1M
Short term investments
$360.6M
$24M
Total assets
$782.7M
$72.5M
Long term debt
$320.4M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 21.87% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 16.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
